Amsparity European Union - English - EMA (European Medicines Agency)

amsparity

pfizer europe ma eeig  - adalimumab - arthritis, rheumatoid; arthritis, psoriatic; psoriasis; spondylitis, ankylosing; uveitis; hidradenitis suppurativa; colitis, ulcerative; crohn disease; arthritis, juvenile rheumatoid - immunosuppressants - rheumatoid arthritisamsparity in combination with methotrexate, is indicated for:the treatment of moderate to severe, active rheumatoid arthritis in adult patients when the response to disease-modifying anti-rheumatic drugs including methotrexate has been inadequate.the treatment of severe, active and progressive rheumatoid arthritis in adults not previously treated with methotrexate.amsparity can be given as monotherapy in case of intolerance to methotrexate or when continued treatment with methotrexate is inappropriate.adalimumab has been shown to reduce the rate of progression of joint damage as measured by x-ray and to improve physical function, when given in combination with methotrexate.juvenile idiopathic arthritispolyarticular juvenile idiopathic arthritis amsparity in combination with methotrexate is indicated for the treatment of active polyarticular juvenile idiopathic arthritis, in patients from the age of 2 years who have had an inadequate response to one or more disease-modifying anti-rheumatic

Vyndaqel European Union - English - EMA (European Medicines Agency)

vyndaqel

pfizer europe ma eeig - tafamidis - amyloidosis - other nervous system drugs, - vyndaqel is indicated for the treatment of transthyretin amyloidosis in adult patients with stage-1 symptomatic polyneuropathy to delay peripheral neurologic impairment.

Pemetrexed Pfizer (previously known as Pemetrexed Hospira UK Limited) European Union - English - EMA (European Medicines Agency)

pemetrexed pfizer (previously known as pemetrexed hospira uk limited)

pfizer europe ma eeig - pemetrexed ditromethamine - carcinoma, non-small-cell lung; mesothelioma - antimetabolites, folic acid analogues - malignant pleural mesotheliomapemetrexed hospira uk limited in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma.non-small cell lung cancerpemetrexed hospira uk limited in combination with cisplatin is indicated for the first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see smpc section 5.1).pemetrexed hospira uk limited is indicated as monotherapy for the second-line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see smpc section 5.

Trumenba European Union - English - EMA (European Medicines Agency)

trumenba

pfizer europe ma eeig - neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily a; neisseria meningitidis serogroup b fhbp (recombinant lipidated fhbp (factor h binding protein)) subfamily b - meningitis, meningococcal - bacterial vaccines, meningococcal vaccines - trumenba is indicated for active immunisation of individuals 10 years and older to prevent invasive meningococcal disease caused by neisseria meningitidis serogroup b.the use of this vaccine should be in accordance with official recommendations.

ReFacto AF European Union - English - EMA (European Medicines Agency)

refacto af

pfizer europe ma eeig - moroctocog alfa - hemophilia a - antihemorrhagics, - treatment and prophylaxis of bleeding in patients with haemophilia a (congenital factor-viii deficiency).refacto af is appropriate for use in adults and children of all ages, including newborns.refacto af does not contain von-willebrand factor, and hence is not indicated in von-willebrand's disease.

Inlyta European Union - English - EMA (European Medicines Agency)

inlyta

pfizer europe ma eeig  - axitinib - carcinoma, renal cell - protein kinase inhibitors - inlyta is indicated for the treatment of adult patients with advanced renal cell carcinoma (rcc) after failure of prior treatment with sunitinib or a cytokine.

Xalkori European Union - English - EMA (European Medicines Agency)

xalkori

pfizer europe ma eeig - crizotinib - carcinoma, non-small-cell lung - antineoplastic agents, - xalkori is indicated for the first-line treatment of adults with anaplastic lymphoma kinase (alk) positive advanced non-small cell lung cancer (nsclc).xalkori is indicated for the treatment of adults with previously treated anaplastic lymphoma kinase (alk) positive advanced non-small cell lung cancer (nsclc).

Tygacil European Union - English - EMA (European Medicines Agency)

tygacil

pfizer europe ma eeig - tigecycline - bacterial infections; skin diseases, bacterial; soft tissue infections - antibacterials for systemic use, - tygacil is indicated in adults and in children from the age of eight years for the treatment of the following infections:complicated skin and soft tissue infections (cssti), excluding diabetic foot infectionscomplicated intra-abdominal infections (ciai)tygacil should be used only in situations where other alternative antibiotics are not suitable.consideration should be given to official guidance on the appropriate use of antibacterial agents. appropriate use of antibacterial agents.

Vfend European Union - English - EMA (European Medicines Agency)

vfend

pfizer europe ma eeig - voriconazole - candidiasis; mycoses; aspergillosis - antimycotics for systemic use - voriconazole, is a broad spectrum, triazole antifungal agent and is indicated in adults and children aged 2 years and above as follows:treatment of invasive aspergillosis;treatment of in candidaemianon-neutropenic patients;treatment of fluconazole-resistant serious invasive candida infections (including c. krusei);treatment of serious fungal infections caused by scedosporium spp. and fusarium spp.vfend should be administered primarily to patients with progressive, possibly life-threatening infections.prophylaxis of invasive fungal infections in high risk allogeneic hematopoietic stem cell transplant (hsct) recipients.

BeneFIX European Union - English - EMA (European Medicines Agency)

benefix

pfizer europe ma eeig - nonacog alfa - hemophilia b - antihemorrhagics, - treatment and prophylaxis of bleeding in patients with haemophilia b (congenital factor-ix deficiency).